<DOC>
	<DOCNO>NCT02462759</DOCNO>
	<brief_summary>The primary objective Part 1 study ass safety tolerability Nusinersen participant SMA eligible participate clinical study ISIS 396443-CS3B ( NCT02193074 ) ISIS 396443-CS4 ( NCT02292537 ) . The secondary objective Part 1 study examine pharmacokinetics ( PK ) Nusinersen participant SMA . The primary objective Part 2 study assess long-term safety tolerability Nusinersen participant SMA participate Part 1 complete End Part 1 Evaluation assessment . The secondary objective Part 2 study examine PK Nusinersen participant SMA participate Part 1 complete End Part 1 Evaluation assessment .</brief_summary>
	<brief_title>A Study Assess Safety Tolerability Nusinersen ( ISIS 396443 ) Participants With Spinal Muscular Atrophy ( SMA ) .</brief_title>
	<detailed_description>Part 2 Open Label extension phase .</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Muscular Atrophy , Spinal</mesh_term>
	<mesh_term>Muscular Atrophy</mesh_term>
	<criteria>Key Genetic documentation 5q SMA homozygous gene deletion , mutation , compound heterozygote . Onset clinical sign symptom consistent SMA ≤6 month age documentation 3 SMN2 copy OR onset clinical sign symptom consistent SMA ≤6 month age , &gt; 7 month age ( 211 day ) screening , documentation 2 SMN2 copy OR onset clinical sign symptom consistent SMA &gt; 6 month age , ≤18 month age screening , documentation 2 3 SMN2 copy . Meets ageappropriate institutional criterion use anesthesia/sedation , use plan study procedure . Medical care , routine immunization meet expect continue meet guideline set Consensus Statement Standard Care SMA , opinion Investigator . Participants 2 SMN2 copy must reside within approximately 9 hour ' groundtravel distance participate study site duration study . Key Meets additional study relate criterion . Any previous exposure ISIS 396443 ; previous dose study previous study ISIS 396443 . Signs symptom SMA present birth within first week birth . Ventilation ≥16 hour per day continuously &gt; 21 day screen . Permanent tracheostomy , implanted shunt CSF drainage , implanted central nervous system ( CNS ) catheter screen . History brain spinal cord disease would interfere LP procedure , CSF circulation , safety assessment . Hospitalization surgery ( e.g. , scoliosis surgery ) , pulmonary event , nutritional support within 2 month prior screen , hospitalization surgery plan study . Clinically significant abnormality hematology clinical chemistry parameter Electrocardiogram ( ECG ) , assess Investigator . Treatment investigational drug SMA ( e.g. , albuterol/salbutamol , riluzole , carnitine , sodium phenylbutyrate , valproate , hydroxyurea ) , biological agent , device within 30 day prior screen . Any history gene therapy , prior antisense oligonucleotide ( ASO ) treatment , cell transplantation . For Part 2 : To eligible participate Part 2 study , participant must meet following eligibility criterion time consent participate Part 2 : Participation Part 1 completion End Part 1 Evaluation assessment . Ability parent ( ) legal guardian ( ) understand purpose risk study provide sign date informed consent Part 2 informed consent form ( ICF ) authorization use confidential health information accordance national local participant privacy regulation . Able complete study procedure , measurement , visit , parent legal guardian/participant adequately supportive psychosocial circumstance , opinion Investigator . Participants exclude Part 2 meet follow exclusion criterion time consent Part 2 study : Any significant change clinical status , include laboratory test , opinion Investigator , would make unsuitable participate Part 2 . The Investigator must reassess subject 's medical fitness participation consider disease would preclude treatment . NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>EMBRACE</keyword>
	<keyword>Spinal Muscular Atrophy</keyword>
	<keyword>SMA</keyword>
</DOC>